In photodynamic therapy, a light-sensitive medicine called verteporfin (Visudyne) is injected into the bloodstream. The medicine collects in the abnormal blood vessels under the macula. Laser light is then shone into the eye, which activates the medicine and causes it to create blood clots that block the abnormal blood vessels.
By sealing the leaky blood vessels, photodynamic therapy slows down:
Photodynamic therapy takes about 20 minutes and may be done in a doctor's office or eye clinic.
The verteporfin medicine used in PDT makes your skin and eyes more sensitive to light. After treatment, avoid direct sunlight for 2 to 5 days. And when you have to be outdoors, wear special dark sunglasses to protect your eyes.
Your doctor will want you to come back for a follow-up exam in about a month.
By limiting the growth of abnormal blood vessels under the macula, photodynamic therapy may help prevent the progression of wet AMD. It does not restore vision to eyes that have already been damaged. But it may help prevent further damage to the retina and further vision loss. People with wet AMD often need multiple treatments to get the full benefits of the therapy.
Some experts think that photodynamic therapy may be more effective and less destructive than laser surgery. Laser treatment almost always causes some immediate, permanent central vision loss (a central blind spot). And laser treatment does not always prevent future growth of abnormal blood vessels. Photodynamic therapy may be better able to target the blood vessels without damaging the nerve cells in the retina and macula.
PDT can lower the risk of severe vision loss by reducing the growth of and leakage from abnormal blood vessels under the retina.2 How well the treatment works depends on where and how the abnormal blood vessels are growing beneath the retina. For some types of wet AMD, the treatment has no detectable benefit.
The effect of PDT in slowing the progress of AMD is often temporary, and the abnormal blood vessels begin leaking again after about 3 months. Most people need multiple treatments to get the full benefits of the therapy.
A severe loss in visual clarity occurs in 1 to 4 out of 100 people treated with PDT. In some cases, vision partially recovers.3
Other side effects that may occur with PDT include:
Photodynamic therapy (PDT) has been shown to be effective for only certain types of wet AMD. The treatment may not work for you.
The effectiveness and long-term consequences of PDT are still being studied.
The verteporfin (Visudyne) dye is an expensive medicine, adding to the overall cost of the treatment. But you must balance this cost against the potential benefit it provides in slowing or reducing the loss of vision from AMD.
- Rosenfeld PJ, et al. (2009). Age-related macular degeneration. In M Yanoff et al., eds., Ophthalmology, 3rd ed., pp. 658–673. Edinburgh: Mosby Elsevier.
- Arnold J, Heriot W (2007). AMD, search date March 2006. Online version of BMJ Clinical Evidence: http://www.clinicalevidence.com.
- Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group (2001). Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of two randomized clinical trials—TAP report 2. Archives of Ophthalmology, 119(2): 198–207.
Last Revised: July 20, 2011
To learn more visit Healthwise.org
© 1995-2012 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.